TG Therapeutics (TGTX) Stock Forecast & Price Target

Compare

2,114 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TGTX Analyst Ratings

Moderate Buy

3 Buy

1 Hold

1 Sell

Based on 5 analysts giving stock ratings to

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TGTX Stock 12 Month Forecast

Average Price Target

$42.00

▲(42.23% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for TG Therapeutics in the last 3 months. The average price target is $42.00 with a high forecast of $60.00 and a low forecast of $15.00. The average price target represents a 42.23% change from the last price of $29.53.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","61":"$61","25.75":"$25.8","37.5":"$37.5","49.25":"$49.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,25.75,37.5,49.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.18,31.55076923076923,33.92153846153846,36.292307692307695,38.66307692307692,41.033846153846156,43.40461538461538,45.77538461538462,48.14615384615385,50.51692307692308,52.887692307692305,55.25846153846154,57.62923076923077,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.18,30.166153846153847,31.15230769230769,32.13846153846154,33.12461538461538,34.11076923076923,35.096923076923076,36.08307692307692,37.06923076923077,38.05538461538461,39.041538461538465,40.027692307692305,41.01384615384615,{"y":42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.18,28.08923076923077,26.998461538461537,25.907692307692308,24.816923076923075,23.726153846153846,22.635384615384616,21.544615384615383,20.453846153846154,19.363076923076925,18.27230769230769,17.181538461538462,16.090769230769233,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.37,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.02,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.78,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.81,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.18,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$42.00

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brian Cheng

J.P. Morgan

$49→$46

Buy

55.77%

Upside

Reiterated

02/02/26

TG Therapeutics price target lowered to $46 from $49 at JPMorganTG Therapeutics price target lowered to $46 from $49 at JPMorgan

Tara Bancroft

TD Cowen

$50

Buy

69.32%

Upside

Reiterated

01/29/26

Analysts Are Bullish on Top Healthcare Stocks: KalVista Pharmaceuticals (KALV), Mirum Pharmaceuticals (MIRM)

Alec Stranahan

Bank of America Securities

$15

Sell

-49.20%

Downside

Reiterated

01/22/26

Analysts Conflicted on These Healthcare Names: Hinge Health, Inc. Class A (NYSE: HNGE), Axsome Therapeutics (NASDAQ: AXSM) and TG Therapeutics (NASDAQ: TGTX)

Emily Bodnar

H.C. Wainwright

$55→$60

Buy

103.18%

Upside

Reiterated

01/14/26

Buy Rating on Briumvi Driven by Strong Commercial Momentum, 2026 Growth Outlook, and Underappreciated Autoimmune Pipeline Optionality

Corinne Johnson

Goldman Sachs

$37→$39

Hold

32.07%

Upside

Reiterated

01/14/26

TG Therapeutics price target raised to $39 from $37 at Goldman SachsTG Therapeutics price target raised to $39 from $37 at Goldman Sachs

Mayank Mamtani

B. Riley Securities

$53→$55

Buy

86.25%

Upside

Reiterated

09/17/25

TG Therapeutics price target raised to $55 from $53 at B. RileyTG Therapeutics price target raised to $55 from $53 at B. Riley

Roger Song

Jefferies

$46

Buy

55.77%

Upside

Reiterated

05/05/25

Jefferies reiterates Buy Rating on TG Therapeutics (TGTX)Jefferies analyst Roger Song reiterated a Buy rating and $46.00 price target on TG Therapeutics (NASDAQ: TGTX).

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

03/03/25

Cantor Fitzgerald reiterates Overweight Rating on TG Therapeutics (TGTX)Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on TG Therapeutics (NASDAQ: TGTX).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brian Cheng

J.P. Morgan

$49→$46

Buy

55.77%

Upside

Reiterated

02/02/26

TG Therapeutics price target lowered to $46 from $49 at JPMorganTG Therapeutics price target lowered to $46 from $49 at JPMorgan

Tara Bancroft

TD Cowen

$50

Buy

69.32%

Upside

Reiterated

01/29/26

Analysts Are Bullish on Top Healthcare Stocks: KalVista Pharmaceuticals (KALV), Mirum Pharmaceuticals (MIRM)

Alec Stranahan

Bank of America Securities

$15

Sell

-49.20%

Downside

Reiterated

01/22/26

Analysts Conflicted on These Healthcare Names: Hinge Health, Inc. Class A (NYSE: HNGE), Axsome Therapeutics (NASDAQ: AXSM) and TG Therapeutics (NASDAQ: TGTX)

Emily Bodnar

H.C. Wainwright

$55→$60

Buy

103.18%

Upside

Reiterated

01/14/26

Buy Rating on Briumvi Driven by Strong Commercial Momentum, 2026 Growth Outlook, and Underappreciated Autoimmune Pipeline Optionality

Corinne Johnson

Goldman Sachs

$37→$39

Hold

32.07%

Upside

Reiterated

01/14/26

TG Therapeutics price target raised to $39 from $37 at Goldman SachsTG Therapeutics price target raised to $39 from $37 at Goldman Sachs

Mayank Mamtani

B. Riley Securities

$53→$55

Buy

86.25%

Upside

Reiterated

09/17/25

TG Therapeutics price target raised to $55 from $53 at B. RileyTG Therapeutics price target raised to $55 from $53 at B. Riley

Roger Song

Jefferies

$46

Buy

55.77%

Upside

Reiterated

05/05/25

Jefferies reiterates Buy Rating on TG Therapeutics (TGTX)Jefferies analyst Roger Song reiterated a Buy rating and $46.00 price target on TG Therapeutics (NASDAQ: TGTX).

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

03/03/25

Cantor Fitzgerald reiterates Overweight Rating on TG Therapeutics (TGTX)Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on TG Therapeutics (NASDAQ: TGTX).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TG Therapeutics

3 Months

xxx

Success Rate

18/33 ratings generated profit

Average Return

+8.94%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +8.94% per trade.

1 Year

Mayank MamtaniB. Riley Securities

Success Rate

20/33 ratings generated profit

Average Return

+51.98%

reiterated a buy rating 5 months ago

Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 60.61% of your transactions generating a profit, with an average return of +51.98% per trade.

2 Years

xxx

Success Rate

26/33 ratings generated profit

Average Return

+86.74%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.79% of your transactions generating a profit, with an average return of +86.74% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TGTX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TGTX has received 10 Buy Ratings, 20 Hold Ratings, and 3 Sell Ratings. TGTX average Analyst price target in the past 3 months is 42.00.

Each month's total comprises the sum of three months' worth of ratings.

TGTX Financial Forecast

TGTX Earnings Forecast

Next quarter’s earnings estimate for TGTX is $0.35 with a range of $0.27 to $0.43. The previous quarter’s EPS was $2.43. TGTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year TGTX has Performed in-line its overall industry.

TGTX Sales Forecast

Next quarter’s sales forecast for TGTX is $191.79M with a range of $183.90M to $200.58M. The previous quarter’s sales results were $161.71M. TGTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year TGTX has Performed in-line its overall industry.

TGTX Stock Forecast FAQ

What is TGTX’s average 12-month price target, according to analysts?

Based on analyst ratings, TG Therapeutics’s 12-month average price target is 42.00.

What is TGTX’s upside potential, based on the analysts’ average price target?

TG Therapeutics has 42.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TGTX a Buy, Sell or Hold?

TG Therapeutics has a consensus rating of Moderate Buy which is based on 3 buy ratings, 1 hold ratings and 1 sell ratings.

What is TG Therapeutics’s price target?

The average price target for TG Therapeutics is 42.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $15.00. The average price target represents 42.23% Increase from the current price of $29.53.

What do analysts say about TG Therapeutics?

TG Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of TGTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

TG Therapeutics (TGTX) Stock Forecast & Price Target

TGTX Analyst Ratings

TGTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering TG Therapeutics

TGTX Analyst Recommendation Trends

TGTX Financial Forecast

TGTX Earnings Forecast

TGTX Sales Forecast

TGTX Stock Forecast FAQ

Detailed List of Analyst Forecasts